Last reviewed · How we verify

Elelyso — Competitive Intelligence Brief

Elelyso (Taliglucerase Alfa) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Enzyme replacement therapy. Area: Rare Disease.

marketed Enzyme replacement therapy Glucocerebroside (substrate); mannose receptors on cell surface Rare Disease Enzyme replacement Live · refreshed every 30 min

Target snapshot

Elelyso (Taliglucerase Alfa) — Pfizer Inc.. Recombinant glucocerebrosidase enzyme replacement therapy that catalyzes hydrolysis of glucocerebroside to glucose and ceramide.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Elelyso TARGET Taliglucerase Alfa Pfizer Inc. marketed Enzyme replacement therapy Glucocerebroside (substrate); mannose receptors on cell surface
agalsidase beta (GZ419828) agalsidase beta (GZ419828) Sanofi marketed Enzyme replacement therapy Alpha-galactosidase A
Replagal (agalsidase alfa) Replagal (agalsidase alfa) Shire marketed Enzyme replacement therapy α-galactosidase A (GLA)
Panzytrat 25.000 FIP-E units of Lipase Panzytrat 25.000 FIP-E units of Lipase Foundation for Liver Research marketed Pancreatic enzyme replacement therapy Triglycerides and dietary lipids
Naglazyme® Naglazyme® Masonic Cancer Center, University of Minnesota marketed Enzyme replacement therapy Arylsulfatase B (ARSB)
Pancrelipase Capsules Pancrelipase Capsules Ohio State University marketed Pancreatic enzyme replacement therapy
Pegvaliase-Pqpz Pegvaliase-Pqpz University of Missouri-Columbia marketed Enzyme replacement therapy Phenylalanine (substrate); phenylalanine ammonia lyase (active enzyme)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Enzyme replacement therapy class)

  1. BioMarin Pharmaceutical · 5 drugs in this class
  2. Sanofi · 3 drugs in this class
  3. JCR Pharmaceuticals Co., Ltd. · 2 drugs in this class
  4. Genzyme, a Sanofi Company · 2 drugs in this class
  5. Pfizer Inc. · 1 drug in this class
  6. Shire · 1 drug in this class
  7. Alexion Pharmaceuticals, Inc. · 1 drug in this class
  8. University of Missouri-Columbia · 1 drug in this class
  9. Eurofarma Laboratorios S.A. · 1 drug in this class
  10. ISU Abxis Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Elelyso — Competitive Intelligence Brief. https://druglandscape.com/ci/elelyso. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: